Anything above $22.50M is all Dacogen aml sales in EU. Last year at this time they wrote down the AVII invesntment. That was around $2M, so earnings should be good. More drugs in clinics, so expenses should be increasing some. HopefullY Dr. M can give some details on spinoff, if it's still in the cards. Looking forward to this announcement.
I am still watching and learning, mostly that we keep talking about a drug that was the product of the previous management team.
Where the heck is Phase lll for SEVERAL new compounds? It has been almost 15 years!
Quick look and things look ok from a 2012 standpoint. They lowered the 2013 revenue royalty number again. This time it is $55M vs $60M two weeks ago. Loss for 2013 is up because the tax benefit is projected to be $5M vs previous $8M estimate.
Hope they give some insight on why the royalty rev is down again.